临床前阿尔茨海默病中淀粉样蛋白病理与髓鞘改变的关联
该研究在71例认知无症状但富集AD风险的成人中,用MRI定量髓鞘水分数及脑脊液β-淀粉样蛋白42、总tau、磷酸化tau181等生物标志物,发现定量弛豫测量与CSF生物标志物水平负相关,且磷酸化tau181/β-淀粉样蛋白42与髓鞘水分数存在年龄交互作用,提示淀粉样蛋白病理可能早期影响白质髓鞘。
要点
- 临床前AD中淀粉样蛋白病理与白质髓鞘定量MRI指标改变相关。
- 磷酸化tau181/β-淀粉样蛋白42水平可调节年龄相关的髓鞘水分数变化。
- 髓鞘改变可能是AD早期特征,或为预防治疗试验提供新标志物。
核心结论
- 淀粉样蛋白病理显著影响白质,这些异常可能代表疾病过程的早期特征。
研究设计与样本
- 在学术研究神经影像中心对71例认知无症状但富集AD风险的成人进行MRI和腰穿脑脊液生物标志物检测。
主要发现
- 19例男性和52例女性参与者平均年龄61.6(6.4)岁。
- 全脑可见广泛的年龄相关髓鞘改变,尤其在前额白质和胼胝体膝部等晚髓鞘化区域。
- 定量弛豫测量与脑脊液AD病理生物标志物水平在全脑白质及AD优先受累区域呈负相关。
- 髓鞘水分数与磷酸化tau181/β-淀粉样蛋白42之间存在显著的年龄-by-生物标志物交互作用。
临床怎么用
- 定量MRI髓鞘测量结合脑脊液生物标志物可能有助于识别临床前AD的白质改变。
- 髓鞘水分数与磷酸化tau181/β-淀粉样蛋白42的交互作用提示需关注年龄对髓鞘改变的影响。
局限性
- 样本量较小(71例)且为认知无症状富集AD风险人群,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The accumulation of aggregated β-amyloid and tau proteins into plaques and tangles is a central feature of Alzheimer disease (AD). While plaque and tangle accumulation likely contributes to neuron and synapse loss, disease-related changes to oligodendrocytes and myelin are also suspected of playing a role in development of AD dementia. Still, to our knowledge, little is known about AD-related myelin changes, and even when present, they are often regarded as secondary to concomitant arteriosclerosis or related to aging. OBJECTIVE: To assess associations between hallmark AD pathology and novel quantitative neuroimaging markers while being sensitive to white matter myelin content. DESIGN, SETTING, AND PARTICIPANTS: Magnetic resonance imaging was performed at an academic research neuroimaging center on a cohort of 71 cognitively asymptomatic adults enriched for AD risk. Lumbar punctures were performed and assayed for cerebrospinal fluid (CSF) biomarkers of AD pathology, including β-amyloid 42, total tau protein, phosphorylated tau 181, and soluble amyloid precursor protein. We measured whole-brain longitudinal and transverse relaxation rates as well as the myelin water fraction from each of these individuals. MAIN OUTCOMES AND MEASURES: Automated brain mapping algorithms and statistical models were used to evaluate the relationships between age, CSF biomarkers of AD pathology, and quantitative magnetic resonance imaging relaxometry measures, including the longitudinal and transverse relaxation rates and the myelin water fraction. RESULTS: The mean (SD) age for the 19 male participants and 52 female participants in the study was 61.6 (6.4) years. Widespread age-related changes to myelin were observed across the brain, particularly in late myelinating brain regions such as frontal white matter and the genu of the corpus callosum. Quantitative relaxometry measures were negatively associated with levels of CSF biomarkers across brain white matter and in areas preferentially affected in AD. Furthermore, significant age-by-biomarker interactions were observed between myelin water fraction and phosphorylated tau 181/β-amyloid 42, suggesting that phosphorylated tau 181/β-amyloid 42 levels modulate age-related changes in myelin water fraction. CONCLUSIONS AND RELEVANCE: These findings suggest amyloid pathologies significantly influence white matter and that these abnormalities may signify an early feature of the disease process. We expect that clarifying the nature of myelin damage in preclinical AD may be informative on the disease's course and lead to new markers of efficacy for prevention and treatment trials.
引用
- Dean DC, Hurley SA, Kecskemeti SR, et al. Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA Neurol. 2017. PMID: 27842175. doi:10.1001/jamaneurol.2016.3232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。